Stock reaction and headline results
Tango Therapeutics, Inc. (NASDAQ:TNGX) saw its stock rise 45% on Monday following the release of initial data from its Phase 1/2 study in pancreatic cancer. The company reported a 92% objective response rate in patients treated with the combination of vopimetostat and daraxonrasib.
Details of the daraxonrasib combination
According to company disclosures, the vopimetostat plus daraxonrasib arm produced a six-month progression-free survival (PFS) rate of 90% among patients with second- and third-line metastatic pancreatic ductal adenocarcinoma. Median PFS has not yet been reached. The trial population for this arm included patients whose tumors were MTAP-deleted and RAS-mutant.
As of May 28, 2026, there were 12 pancreatic cancer patients in the vopimetostat plus daraxonrasib arm who were response-evaluable with at least 14 weeks of follow-up. The combination reached a 100% disease control rate, and 9 of 11 responses were confirmed. Dosing in this arm consisted of either vopimetostat 200 mg or 250 mg once daily plus daraxonrasib 100 mg once daily.
The trial cohort for the daraxonrasib combination included patients with advanced disease characteristics - 70% had liver metastases in that arm - and more than half of the patients received the regimen as third-line treatment.
Data from the zoldonrasib arm
In a separate arm combining vopimetostat with zoldonrasib, the company reported data on 27 evaluable pancreatic cancer patients. That combination produced a 52% objective response rate and a 74% six-month PFS rate.
Tolerability
Both combination regimens were generally well tolerated, with the majority of adverse events graded as 1 or 2 in severity. For the daraxonrasib-containing arm, the most frequently reported treatment-related adverse events were rash, stomatitis/mucositis, and diarrhea. There were no related Grade 4 or Grade 5 adverse events reported, and no patients discontinued treatment due to adverse events in either combination arm.
Regulatory and development plans
Tango indicated plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development specifically for first-line MTAP-deleted pancreatic cancer. The company said it expects to finalize the Phase 3 trial design in the second half of 2026.
Context and implications
The reported response and disease control rates in these early datasets have driven investor enthusiasm, reflected in the stock’s sharp intraday gain. The company’s move toward a Phase 3 program for the daraxonrasib combination signals an intent to pursue registration-enabling development in the defined molecular subset of pancreatic cancer patients.
Remaining limitations in the data
The information released to date reflects initial results from a Phase 1/2 study with limited patient numbers and follow-up. Median PFS for the daraxonrasib combination has not been reached, and confirmation in larger randomized studies will be required to validate durability and broader applicability of the findings.